ArticleCancer management and research2021

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer.

Peter A Fasching et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.